Dermatologic Therapy最新文献

{"title":"5-Aminolevulinic Acid Photodynamic Therapy With Broadband Light Versus Broadband Light Alone in Treating Rosacea: A Retrospective, Controlled Study","authors":"Weinan Zhang,&nbsp;Luoyingzi Xie,&nbsp;Caifeng Wang,&nbsp;Yamin Li,&nbsp;Yingyue Qin,&nbsp;Jie Gong,&nbsp;Fanxi Zhang,&nbsp;Shulei Liu,&nbsp;Xu He,&nbsp;Zhiqiang He","doi":"10.1155/dth/6600228","DOIUrl":"https://doi.org/10.1155/dth/6600228","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Rosacea is a chronic inflammatory skin disorder primarily affecting the face. While conventional treatments include drug interventions and light device interventions. However, their efficacy is often limited. New therapeutic approaches are therefore needed. In this study, we aimed to compare the efficacy and safety of broadband light (BBL) with photodynamic therapy (PDT) (BBL-PDT) and BBL therapy alone in treating rosacea.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included 52 patients with rosacea treated with either BBL therapy alone or BBL-PDT. Efficacy was assessed using Investigator’s Global Assessment (IGA) success, Clinical Erythema Assessment (CEA) success, telangiectasia improvement, lesion counts, and Rosacea Quality of Life (RosaQoL). Adverse reactions were also recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At the 12th week of treatment, IGA success was achieved in 26.92% patients in the BBL group and 69.23% in the BBL-PDT group (<i>P</i> = 0.002); CEA success rates were 61.54% (BBL) and 73.08% (BBL-PDT) (<i>P</i> = 0.38). Flushing improvement occurred in 65.38% (BBL) and 61.54% (BBL-PDT) (<i>P</i> = 0.77), whereas telangiectasia improvement occurred in 57.69% (BBL) and 61.54% (BBL-PDT) (<i>P</i> = 0.78). The BBL-PDT group showed significantly fewer lesions (<i>P</i>  &lt;  0.001) and lower RosaQoL scores (<i>P</i> = 0.003). However, they reported higher levels of pain (<i>P</i>  &lt;  0.0001) and more local adverse effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BBL-PDT is more effective than BBL alone in reducing inflammatory lesions and improving quality of life in rosacea.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6600228","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145824626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Timolol in Dermatology: Applications and Advances","authors":"Wang Yu,&nbsp;Wang Yue,&nbsp;Tang Shuanglu,&nbsp;Luo Yuanyuan,&nbsp;Huang Liping,&nbsp;Yu Qiuyue,&nbsp;Sun Jing,&nbsp;Tang Jing,&nbsp;Feng Yuebi,&nbsp;Mu Yunzu","doi":"10.1155/dth/5812080","DOIUrl":"https://doi.org/10.1155/dth/5812080","url":null,"abstract":"<p>Timolol, a nonselective <i>β</i>-adrenergic receptor blocker approved by the US Food and Drug Administration (FDA) in 1978 for glaucoma treatment, exhibits multiple pharmacological effects including vasoconstriction, promotion of epithelial healing, anti-inflammatory, and antioxidant properties. Although systemic administration is associated with significant adverse effects, its topical formulations have emerged as a research focus in dermatological therapy due to their superior safety profile and demonstrated efficacy. This article provides a systematic review of the current evidence-based advancements in the topical application of timolol in dermatology, aiming to offer a theoretical foundation for clinical practice.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5812080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variations in Minimal Erythema Dose of 308-nm Excimer Laser Therapy Across Anatomical Sites in Asian Patients With Vitiligo","authors":"Jiyuan Wu,&nbsp;Jingjing Wang,&nbsp;Meihua Chen,&nbsp;Ting Yao,&nbsp;Yan Liu,&nbsp;Chen Liu","doi":"10.1155/dth/2174848","DOIUrl":"https://doi.org/10.1155/dth/2174848","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>To investigate anatomical site-specific differences in the minimal erythema dose (MED) of 308-nm excimer laser therapy among Asian patients with vitiligo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis of MED data from 378 patients was conducted. Nonparametric tests were used to compare MED values across six anatomical sites and facial subregions, while Spearman correlation assessed influencing factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MED values in lesional skin were significantly higher than in normal skin. Site-specific MED variations were observed, ranked from lowest to highest as follows: face, trunk, neck, scalp, extremities, and acral regions (hands/feet). Within facial subregions, periorbital and perioral mucosal areas exhibited 15%–25% lower MED values compared with other regions. Skin phototype, season, and age were independent predictors of MED (<i>P</i> &lt; 0.05), whereas sex, family history, and lesion size showed no significant correlation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MED values vary significantly across anatomical sites in Asian patients with vitiligo. Clinical phototherapy protocols should incorporate site-specific and skin type–adjusted dosing strategies, with particular attention to the lower MED thresholds of mucosal regions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2174848","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Characterization of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE): A Retrospective Study From a Tertiary Care Hospital","authors":"Luis Carrasco-Gómez,&nbsp;Alba Lecumberri,&nbsp;José María Renilla-Arroyo,&nbsp;Belén de la Hoz-Caballer,&nbsp;Laura Díaz-Montalvo,&nbsp;Javier Martínez-Botas,&nbsp;Alicia Barra-Castro,&nbsp;Montserrat Fernández-Guarino","doi":"10.1155/dth/1433440","DOIUrl":"https://doi.org/10.1155/dth/1433440","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a rare hypersensitivity reaction characterized by symmetric erythematous rashes in intertriginous regions, triggered by systemic drugs. Although self-limiting, SDRIFE can significantly impact quality of life, requiring accurate diagnosis and management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to describe the clinical characteristics, diagnostic approaches, and implicated pharmacological agents in the largest reported SDRIFE series, providing insights to improve diagnosis and treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A retrospective observational study was conducted between 2018 and 2024. Data on demographics, clinical features, implicated drugs, and diagnostic tests—including drug provocation tests (DPTs), lymphocyte transformation tests (LTTs), and intradermal tests—were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 41 patients, the mean age was 66.6 years, with frequent polypharmacy complicating diagnosis. Beta-lactam antibiotics and iodinated contrast agents were the most implicated drugs. Nine previously unreported drugs were identified as triggers. DPT confirmed causality in six cases, and LTT aided in three complex cases. Avoidance of the suspected drug or pharmacological group was the main therapeutic measure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Systematic medication reviews and standardized protocols are crucial for SDRIFE diagnosis. DPT remains the gold standard, while LTT adds value in complex cases, avoiding unnecessary drug restrictions and expanding therapeutic options.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1433440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Orienting Skin Grafts Parallel to Skin Tension Lines and Color Matching on Quality of Life in Patients With Basal Cell Carcinoma (Skin Types II–IV)","authors":"Hilayda Karakök Kışla,&nbsp;Mustafa Gundogdu,&nbsp;Ceren Efe Sayın","doi":"10.1155/dth/9105783","DOIUrl":"https://doi.org/10.1155/dth/9105783","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While the importance of skin tension lines in planning excisions is well-documented, its importance in planning grafts is less investigated. This study investigates the effect of orienting grafts along with skin tension lines on quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with basal cell carcinoma and treated with either no specific attention for orientation (Group 1, <i>n</i> = 40) or skin tension line–oriented grafting (Group 2, <i>n</i> = 31) were evaluated by Skin Cancer Quality of Life Impact Tool (SCQOLIT) and the Dermatology Quality of Life Index (DLQI) 3 months after surgery. Cosmetic outcome was evaluated by a visual analog scale (VAS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-one patients were included (34 males [47.9%] and 37 females [52.1%]; mean age 66.55 ± 9.43). The mean VAS score was 5.64 ± 0.94 for Group 1 and 6.13 ± 0.99 for Group 2. The mean DLQI score was 1 (0–22) for both groups, and the mean SCQOLIT scores were 10 (0–27) for Group 1 and 10 (0–32) for Group 2. While VAS scores significantly differed between groups (<i>p</i> &lt; 0.05), no difference in quality of life was observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Tension line–oriented grafting yielded better cosmetic outcomes without demonstrating superiority in terms of quality of life.</p>\u0000 \u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT06894056.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9105783","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Efficacy and Safety of Nonablative 1550-nm Fractional Laser for Facial Syringoma: A Case Series Study","authors":"Tae Min Kim,&nbsp;So young Kwon,&nbsp;Soyun Cho","doi":"10.1155/dth/6337375","DOIUrl":"https://doi.org/10.1155/dth/6337375","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Syringoma has been known to recur following conventional treatments like cryotherapy and CO₂ laser. The risk of side effects, such as erythema, edema, scarring, and postinflammatory hyperpigmentation, results in unsatisfactory outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the efficacy and safety of 1550-nm nonablative fractional laser for treating syringoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed the medical records of syringoma patients who underwent 1550-nm fractional laser treatment. Two blinded dermatologists assessed the treatment efficacy of syringoma based on randomized clinical photographs before and after treatment, using the Periorbital Syringoma Severity Index (PSSI) score and a Global Improvement Scale. Additionally, the types and duration of any side effects occurring after the treatment were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 8 patients underwent 22 sessions of 1550-nm fractional laser treatment, averaging 2.75 sessions per patient (median, 2 sessions; range, 1–6 sessions). The female-to-male ratio was 7 : 1, with 3 patients (37.5%) having prior experience with CO₂ laser. The pretreatment PSSI score improved from 4.00 to 2.88 after treatment (<i>p</i> = 0.03). Notably, 2 patients (25.0%) showed marked improvement, and 3 patients (37.5%) exhibited a moderate response. There was a strong correlation between the number of sessions and both the Global Improvement Scale (<i>r</i> = 0.783, <i>p</i> = 0.02) and PSSI score reduction (<i>r</i> = 0.619, <i>p</i> = 0.10). No scarring or dyspigmentation was observed postlaser treatment, and transient edema in 3 patients resolved on average after 13.7 days (median, 7 days).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although this study is limited by its retrospective design and small sample size, its findings underscore the clinical efficacy of the 1550-nm nonablative fractional laser for the treatment of syringoma. Considering its nonablative nature and short downtime, the 1550-nm fractional laser is a safe and effective treatment alternative.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6337375","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic Effects of Fractional CO2 Laser and Recombinant Humanized Type III Collagen (rhCol III) in Atrophic Acne Scar Treatment: Activation of MAPK Pathway and Enhanced Collagen Remodeling","authors":"Li Gu,&nbsp;Jing Wang,&nbsp;Rong Guo,&nbsp;Zhinan Shi,&nbsp;Zhiyi Xu,&nbsp;Shu Zhou,&nbsp;Jingting Zhao,&nbsp;Liqun Gu,&nbsp;Bingrong Zhou,&nbsp;Hui Hua","doi":"10.1155/dth/6736692","DOIUrl":"https://doi.org/10.1155/dth/6736692","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Fractional CO&lt;sub&gt;2&lt;/sub&gt; laser (FCL) is widely used for resurfacing the skin with atrophic acne scars. This study aims to explore the synergistic efficacy of recombinant humanized type III collagen (rhCol III) on FCL in treating atrophic acne scars.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 20 patients with facial atrophic acne scars from two medical institutions were treated with a single session of full-face FCL. One month post-FCL, they were randomly assigned to the FCL + rhCol III group and FCL + NC group, with 10 cases per group. Patients in the FCL + rhCol III group received dermal injections with 4 mg of rhCol III dissolved in 1.2 mL of saline on one side of the face, and those in the FCL + NC group were similarly injected with the same amount of saline. Dermal injections were performed three times, with an interval of 4 weeks. Therapeutic efficacy was assessed using the Echelle d’évaluation clinique des cicatrices d’acné (ECCA) grading scale and the Global Scarring Grading System (GSS). Human dermal fibroblasts (HDFs) were cultured in vitro, and induced with FCL and rhCol III. Immunofluorescence was utilized to detect the expression of type I and III collagens. RNA-sequencing (RNA-seq) identified differentially expressed genes (DEGs) in HDFs induced with FCL combined with rhCol III.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 18 eligible patients were enrolled and followed up. Post-treatment, patients in the FCL + rhCol III group were graded with a significantly lower ECCA score (77.50 ± 15.07 vs. 106.1 ± 21.25, &lt;i&gt;p&lt;/i&gt; &lt; 0.05), but a higher scar improvement rate (40.23% ± 13.23% vs. 23.26% ± 19.69%, &lt;i&gt;p&lt;/i&gt; &lt; 0.05) than those in the FCL + NC group. Classified by the type of acne scars, patients with boxcar and icepick acne scars significantly benefited more from FCL combined with rhCol III than those in the FCL + NC group and showed a significantly reduced ECCA score and an increased scar improvement rate (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). Similarly, patients in the FCL + rhCol III group also exhibited significantly a lower GSS score (7.75 ± 1.75 vs. 10.00 ± 2.33, &lt;i&gt;p&lt;/i&gt; &lt; 0.05) and a higher scar improvement rate (43.30% ± 10.49% vs. 25.59% ± 18.34%, &lt;i&gt;p&lt;/i&gt; &lt; 0.05). In vitro experiments showed that the induction of FCL combined with rhCol III significantly upregulated type I and III collagens in HDFs. RNA-seq unmasked that MAPK signaling pathway was activated in HDFs induced with FCL combined with rhCol III.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;FCL combined with rhCol","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6736692","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National, Regional, and Global Epidemiology of Alopecia Areata: A Systematic Analysis Based on Modeling Study","authors":"Shuntong Kang,&nbsp;Dingyao Zhang,&nbsp;Yaqing Huang,&nbsp;Jingru Tian,&nbsp;Qianjin Lu","doi":"10.1155/dth/6716671","DOIUrl":"https://doi.org/10.1155/dth/6716671","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Alopecia areata (AA) is a prevalent nonscarring hair loss disease affecting the scalp and body hair. However, previous studies have reported conflicting findings regarding its epidemiology. We aimed to quantify the global, regional, and country-specific estimates of AA epidemiology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a comprehensive systematic review of published studies reporting on the incidence and prevalence of AA. We searched four electronic databases from January 1, 1992 to October 20, 2023: PubMed, Embase, Web of Science, and China National Knowledge Infrastructure. A Bayesian hierarchical linear mixed model was employed to determine the epidemiological estimates, accounting for variations in regions, diagnostic types, and age groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>73 studies met the inclusion criteria. The incidence varied across different geographical locations and age strata. The overall point prevalence and diagnosed population of AA were estimated at 1.93% (0.17%–5.91%) and 15.05 million people, respectively. The United Kingdom, Saudi Arabia, Iraq, and Egypt exhibited the highest prevalence. Globally, approximately 10.29 million adults and 4.76 million children had AA, with a prevalence of 1.98% (0.17%–6.07%) for adults and 1.83% (0.16%–5.58%) for children. Women were more likely to suffer from it. The global prevalence in females was 2.25% (0.20%–7.03%), affecting 8.69 million individuals, whereas for males, the estimates were 1.62% (0.14%–4.80%), impacting 6.36 million individuals. Variations in the epidemiological results might also stem from the chosen method of prevalence estimation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Epidemiological data for AA were absent in 89.1% of countries globally. The epidemiology varied across gender and age groups and was unevenly distributed among geographical regions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6716671","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145626156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder (PCSM-LPD): Dermoscopic Clues to Address Its Diagnosis and Their Interobserver Reliability","authors":"Corrado Zengarini,&nbsp;Giulia Bandini,&nbsp;Marco Adriano Chessa,&nbsp;Alba Guglielmo,&nbsp;Martina Mussi,&nbsp;Vieri Grandi,&nbsp;Claudio Agostinelli,&nbsp;Elena Sabattini,&nbsp;Bianca Maria Piraccini,&nbsp;Alessandro Pileri","doi":"10.1155/dth/9975973","DOIUrl":"https://doi.org/10.1155/dth/9975973","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-LPD) is a rare lymphoid proliferation whose dermoscopic features are poorly defined, making diagnosis challenging. This study aims to identify the most common dermoscopic features of PCSM-LPD, assess their diagnostic accuracy, and evaluate interobserver reproducibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective study in a referral clinic, including patients with histologically confirmed PCSM-LPD and a control group of various cutaneous lymphomas. Two experienced dermatologists independently reviewed dermoscopic images. Key dermoscopic features were identified and compared between the groups. Interoperator reproducibility was measured using Cohen’s Kappa. Diagnostic accuracy and agreement were the primary outcome measures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We analysed 18 PCSM-LPD cases and 18 controls. Serpentine vessels were the most common feature in PCSM-LPD, with a sensitivity of 100% and specificity of 76.5%. Keratin plugs had a sensitivity of 88.9% and a specificity of 77.8%. A yellow-orange background was also significant, with 100% sensitivity and 77.8% specificity. Interoperator agreement showed low to moderate Kappa values, with better agreement for vessel presence and keratin plugs but lower for vessel type and distribution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Serpentine vessels, keratin plugs, and yellow-orange background characteristics were found to be very sensitive and specific; however, their usability needs to be contextualised for diagnosing PCSM-LPD. Finally, despite high diagnostic accuracy, the interobserver agreement seems inconsistent, highlighting the need for standardised training. Further studies are necessary to validate these findings and improve diagnostic consistency in clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9975973","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145626487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prevalence and Clinical Characteristics of PHACE Syndrome in Facial Segmental Hemangiomas: A Single-Center Retrospective Study","authors":"Jingjing Sun,&nbsp;Rui Chang,&nbsp;Shih-Jen Chang,&nbsp;Lei Chang,&nbsp;Qianyi Chen,&nbsp;Gang Ma,&nbsp;Yajing Qiu,&nbsp;Xiaoxi Lin","doi":"10.1155/dth/4078903","DOIUrl":"https://doi.org/10.1155/dth/4078903","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>PHACE syndrome is a neurocutaneous syndrome characterized by large facial segmental hemangiomas as the most typical manifestation. Its prevalence in East Asian is not well studied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The retrospective study included 98 infants with facial segmental hemangiomas who underwent brain MRI/MRA, cardiac ultrasound, and ophthalmology examinations. The prevalence along with documentation of its clinical characteristics of PHACE syndrome was analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 98 patients, 5 (5.1%) were diagnosed with “definite” PHACE, while none (0.0%) exhibited “possible” PHACE. Most patients with PHACE syndrome had 2 or more segments, of which the frontotemporal segment was most frequently involved. Structural brain anomalies were identified in two patients, four exhibited cerebrovascular anomalies, four displayed cardiovascular anomalies, and two presented ocular anomalies. Following standardized oral propranolol therapy, all patients showed significant regression. One patient received laser treatment for a residual hemangioma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The prevalence of PHACE syndrome in facial segmental hemangiomas was 5.1%, predominantly characterized by anomalies in the cerebrovascular and cardiovascular systems. Collaborative multidisciplinary diagnosis and treatment are critical for PHACE patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4078903","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145626486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}